RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $128
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has maintained an Outperform rating on Abbott Laboratories (NYSE:ABT) and increased the price target from $119 to $128.
January 11, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on Abbott Laboratories and raises the price target from $119 to $128.
The increase in price target by RBC Capital suggests a positive outlook on Abbott Laboratories' stock, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100